Emergent BioSolutions Inc. has won a $29.7 million, three-year contract to continue to develop its next-generation anthrax vaccine candidate. (EBS) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Original source: http://feeds.bizjournals.com/~r/vertical_36/~3/403965430/daily95.html